DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
- Description:
Fluorescent 5-HT2A receptor antagonist
Clozapine (HB1607)
Description:Prototypic, atypical antipsychotic, binds to both serotonin and dopamine receptors
Purity:>99%
Olanzapine (HB1786)
Description:5-HT2A and D2 antagonist. Potent DREADD agonist. Atypical antipsychotic.
Purity:>99%
Spiperone hydrochloride (HB1656)
Description:Selective D2-like receptor antagonist. 5-HT2A antagonist.
Purity:>98%
Ziprasidone hydrochloride (HB1753)
Description:5-HT2A and D2 antagonist. Atypical antipsychotic.
Purity:>99%
Zotepine (HB1778)
Description:5-HT2A and dopamine D2 receptor antagonist. Atypical antipsychotic.
Purity:>99%